SecBot SecBot
425 ·Filed Nov 12, 2026

FULC

Fulcrum Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed4d 11h ago SEC0001193125-26-458402
Rule 425 M&A communications
Actionable Insight • Neutral

The $7M asset sale is a small, conditional transaction that modestly boosts the cash component of the merger consideration. Monitor the merger vote and regulatory clearances; the dividend increase is a secondary effect.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$3.77
T+0 close · Nov 12, 2026 · via day close
Latest settled
−1.59%
T+1 · $3.71
Vs SPY
+0.32%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $3.77entry
  2. T+1 · 20h ago −1.59%α +0.32% · $3.71
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fulcrum Therapeutics entered into an asset purchase agreement to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third party for approximately $7.0 million in cash. The sale is contingent on the closing of Fulcrum's pending merger with Slate Medicines (or, if the merger is terminated, upon receipt of necessary approvals). Proceeds will be placed into escrow and credited to Fulcrum's net cash, increasing the expected cash dividend to Fulcrum stockholders in connection with the merger.

Key Financial Metrics

Deal Value
$7.0M

Key Facts

  • Fulcrum and Slate entered into an asset purchase agreement on November 7, 2026 for Fulcrum's early-stage HbF assets.
  • Sale price is approximately $7.0 million in cash.
  • Closing is contingent on consummation of the Fulcrum-Slate merger (Merger Agreement dated August 16, 2026) or, if merger is terminated, upon receipt of necessary approvals.
  • Proceeds will be funded into escrow before the merger closes and credited to Fulcrum's net cash, increasing the expected cash dividend to Fulcrum stockholders.

Financial Impact

$7.0 million cash sale of early-stage HbF assets; proceeds increase net cash and expected merger dividend.

cashdividend

Risk Factors

  • Asset sale is contingent on merger closing; if merger fails, sale requires separate approvals and may not close.
  • The $7M amount is small relative to typical biotech deal sizes and may not materially change the merger's economics.

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001193125-26-458402
Document: 0001193125-26-458402-index-headers.html0001193125-26-458402
Document: 0001193125-26-458402-index.html0001193125-26-458402
Document: 0001193125-26-458402.txt0001193125-26-458402

Track record

23 reports on FULC

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  4. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  5. Nov 12, 20264d ago 425 Neutral 3/10 Viewing Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  6. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  7. Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
  8. Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
  9. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
  10. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026